Literature DB >> 23684799

PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.

Michael J Metzger1, Barry L Stoddard, Raymond J Monnat.   

Abstract

Double-strand breaks (DSBs) in chromosomal DNA can induce both homologous recombination (HR) and non-homologous end-joining (NHEJ). Recently we showed that single-strand nicks induce HR with a significant reduction in toxicity and mutagenic effects associated with NHEJ. To further investigate the differences and similarities of DSB- and nick-induced repair, we used an integrated reporter system in human cells to measure HR and NHEJ produced by the homing endonuclease I-AniI and a designed 'nickase' variant that nicks the same target site, focusing on the PARP and HR repair pathways. PARP inhibitors, which block single-strand break repair, increased the rate of nick-induced HR up to 1.7-fold but did not affect DSB-induced HR or mutNHEJ. Additionally, expression of the PALB2 WD40 domain in trans acted as a dominant-negative inhibitor of both DSB- and nick-induced HR, sensitized cells to PARP inhibition, and revealed an alternative mutagenic repair pathway for nicks. Thus, while both DSB- and nick-induced HR use a common pathway, their substrates are differentially processed by cellular factors. These results also suggest that the synthetic lethality of PARP and BRCA may be due to repair of nicks through an error prone, NHEJ-like mechanism that is active when both PARP and HR pathways are blocked.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23684799      PMCID: PMC3683368          DOI: 10.1016/j.dnarep.2013.04.004

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  36 in total

1.  Stimulation of homologous recombination through targeted cleavage by chimeric nucleases.

Authors:  M Bibikova; D Carroll; D J Segal; J K Trautman; J Smith; Y G Kim; S Chandrasegaran
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

2.  The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA.

Authors:  G Gradwohl; J M Ménissier de Murcia; M Molinete; F Simonin; M Koken; J H Hoeijmakers; G de Murcia
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts.

Authors:  A Semionov; D Cournoyer; T Y Chow
Journal:  Nucleic Acids Res       Date:  1999-11-15       Impact factor: 16.971

Review 4.  Instability and decay of the primary structure of DNA.

Authors:  T Lindahl
Journal:  Nature       Date:  1993-04-22       Impact factor: 49.962

5.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Authors:  Niklas Schultz; Elena Lopez; Nasrollah Saleh-Gohari; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

6.  3-Aminobenzamide synergistically increases sister-chromatid exchanges in cells exposed to methyl methanesulfonate but not to ultraviolet light.

Authors:  W F Morgan; J E Cleaver
Journal:  Mutat Res       Date:  1982-07       Impact factor: 2.433

7.  Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells.

Authors:  P Rouet; F Smih; M Jasin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

8.  Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture.

Authors:  J Mendeleyev; E Kirsten; A Hakam; K G Buki; E Kun
Journal:  Biochem Pharmacol       Date:  1995-08-25       Impact factor: 5.858

9.  Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks.

Authors:  Yun-Gui Yang; Ulrich Cortes; Srinivas Patnaik; Maria Jasin; Zhao-Qi Wang
Journal:  Oncogene       Date:  2004-05-06       Impact factor: 9.867

10.  Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects.

Authors:  Cherie L Ramirez; Michael T Certo; Claudio Mussolino; Mathew J Goodwin; Thomas J Cradick; Anton P McCaffrey; Toni Cathomen; Andrew M Scharenberg; J Keith Joung
Journal:  Nucleic Acids Res       Date:  2012-02-28       Impact factor: 16.971

View more
  25 in total

1.  Assaying break and nick-induced homologous recombination in mammalian cells using the DR-GFP reporter and Cas9 nucleases.

Authors:  Lianne E M Vriend; Maria Jasin; Przemek M Krawczyk
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Authors:  Silvia Maifrede; Kayla Martin; Paulina Podszywalow-Bartnicka; Katherine Sullivan-Reed; Samantha K Langer; Reza Nejati; Yashodhara Dasgupta; Michael Hulse; Daniel Gritsyuk; Margaret Nieborowska-Skorska; Lena N Lupey-Green; Huaqing Zhao; Katarzyna Piwocka; Mariusz A Wasik; Italo Tempera; Tomasz Skorski
Journal:  Mol Cancer Res       Date:  2017-06-20       Impact factor: 5.852

3.  Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.

Authors:  Elizabeth Hewlett; Monika Toma; Katherine Sullivan-Reed; John Gordo; Tomasz Sliwinski; Alexei Tulin; Wayne E Childers; Tomasz Skorski
Journal:  Med Chem Res       Date:  2020-04-19       Impact factor: 1.965

4.  Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.

Authors:  K Veskimäe; S Staff; A Grönholm; M Pesu; M Laaksonen; M Nykter; J Isola; J Mäenpää
Journal:  Tumour Biol       Date:  2016-05-07

5.  Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.

Authors:  Giulia Pavani; Anna Fabiano; Marine Laurent; Fatima Amor; Erika Cantelli; Anne Chalumeau; Giulia Maule; Alexandra Tachtsidi; Jean-Paul Concordet; Anna Cereseto; Fulvio Mavilio; Giuliana Ferrari; Annarita Miccio; Mario Amendola
Journal:  Blood Adv       Date:  2021-03-09

6.  Base excision repair defects invoke hypersensitivity to PARP inhibition.

Authors:  Julie K Horton; Donna F Stefanick; Rajendra Prasad; Natalie R Gassman; Padmini S Kedar; Samuel H Wilson
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

7.  Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.

Authors:  Moureq Alotaibi; Khushboo Sharma; Tareq Saleh; Lawrence F Povirk; Eric A Hendrickson; David A Gewirtz
Journal:  Radiat Res       Date:  2016-03-02       Impact factor: 2.841

8.  Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.

Authors:  Naoki Kawahara; Kenji Ogawa; Mika Nagayasu; Mai Kimura; Yoshikazu Sasaki; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-09-27

9.  Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?

Authors:  Howard Lopes Ribeiro Junior; Roberta Taiane Germano de Oliveira; Daniela de Paula Borges; Marília Braga Costa; Izabelle Rocha Farias; Antônio Wesley Araújo Dos Santos; Silvia Maria Meira Magalhães; Ronald Feitosa Pinheiro
Journal:  Med Oncol       Date:  2019-10-30       Impact factor: 3.064

10.  Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Authors:  Margaret Nieborowska-Skorska; Katherine Sullivan; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Grazyna Hoser; Silvia Maifrede; Esteban Martinez; Daniela Di Marcantonio; Elisabeth Bolton-Gillespie; Kimberly Cramer-Morales; Jaewong Lee; Min Li; Artur Slupianek; Daniel Gritsyuk; Sabine Cerny-Reiterer; Ilona Seferynska; Tomasz Stoklosa; Lars Bullinger; Huaqing Zhao; Vera Gorbunova; Katarzyna Piwocka; Peter Valent; Curt I Civin; Markus Muschen; John E Dick; Jean Cy Wang; Smita Bhatia; Ravi Bhatia; Kolja Eppert; Mark D Minden; Stephen M Sykes; Tomasz Skorski
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.